September 24th 2024
Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Study: Curcumin Nanoparticles as a Photoprotective Adjuvant
August 24th 2021Curcumin has a long history as an effective treatment for everything from chronic pain to skin infections. Nanoparticle encapsulation shows promise in meeting that challenge and opening the way for a safe, effective adjuvant to sunscreen.
FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma
August 6th 2021The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.
Valisure CEO Shares Thoughts on Johnson & Johnson Sunscreen Recall
August 4th 2021In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.
Doctors Aim for Better Understanding of Pediatric Melanoma Through Registry
August 3rd 2021In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).
Physician Provides Update on Benzene Contamination in Sunscreens
July 29th 2021In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.
Physician Weighs in on Sunscreen Contamination Controversy
May 28th 2021Christopher Bunick, MD, PhD, associate professor of dermatology, Yale University and Dermatology Times® editorial advisory board member, weighs in on a recent report revealing certain batches of various sunscreen and after-sun care products were contaminated with benzene, a carcinogen.
Valisure Highlights Controversy of Benzene Contamination in Sunscreen Products
May 26th 2021David Light, founder and CEO of Valisure, the independent lab that discovered the presence of benzene in multiple brands and batches of sunscreen, sits down with Dermatology Times to discuss the reports' findings and the impact this news will have on the sun protection industry.